{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T04:15:37Z","timestamp":1749010537687,"version":"3.41.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","license":[{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1097\/cm9.0000000000001986","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T13:04:44Z","timestamp":1646831084000},"page":"2628-2630","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Etanercept in axial spondyloarthritis"],"prefix":"10.1097","volume":"135","author":[{"given":"Gui","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,11,5]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1080\/14712598.2017.1347156","article-title":"Etanercept for treating axial spondyloarthritis","volume":"17","author":"Guillot","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/19420862.2017.1388483","article-title":"Manufacturing history of etanercept (Enbrel\u00ae): consistency of product quality through major process revisions","volume":"10","author":"Hassett","year":"2018","journal-title":"mAbs"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"621247","DOI":"10.3389\/fphar.2021.621247","article-title":"Biologics during pregnancy and breastfeeding among women with rheumatic diseases: safety clinical evidence on the road","volume":"12","author":"Beltagy","year":"2021","journal-title":"Front Pharmacol"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"566160","DOI":"10.3389\/fmed.2020.566160","article-title":"Head-to-head comparison of etanercept vs. adalimumab in the treatment of ankylosing spondylitis: an open-label randomized controlled crossover clinical trial","volume":"7","author":"Wei","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"1759720X20987700","DOI":"10.1177\/1759720X20987700","article-title":"Sustained clinical response and safety of etanercept in patients with early axial spondyloarthritis: 10-year results ofthe ESTHER trial","volume":"13","author":"Proft","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"(Supp 6)","key":"R7-20250603","doi-asserted-by":"crossref","first-page":"vi18","DOI":"10.1093\/rheumatology\/key176","article-title":"Defining the target: clinical aims in axial spondyloarthritis","volume":"57","author":"Marzo-Ortega","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/art.41607","article-title":"Is treatment in patients with suspected nonradiographic axial spondyloarthritis effective? Six-month results of a placebo-controlled trial","volume":"73","author":"Rusman","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R9-20250603","first-page":"1","article-title":"Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study","volume":"7","author":"Cantini","year":"2013","journal-title":"Biologics"},{"key":"R10-20250603","first-page":"884","article-title":"Efficiency of dose reduction strategy of etanercept in patients with axial spondyloarthritis","volume":"36","author":"Lian","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/art.40786","article-title":"Progression of structural damage in the sacroiliac joints in patients with early axial spondyloarthritis during long-term anti-tumor necrosis factor treatment: six-year results of continuous treatment with etanercept","volume":"71","author":"Rios Rodriguez","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/annrheumdis-2017-211605","article-title":"Modification of structural lesions on MRI of the sacroiliac joints by etanercept in the EMBARK trial: a 12-week randomised placebo-controlled trial in patients with non-radiographic axial spondyloarthritis","volume":"77","author":"Maksymowych","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/acr.23276","article-title":"Effects of long-term etanercept treatment on clinical outcomes and objective signs of inflammation in early nonradiographic axial spondyloarthritis: 104-week results from a randomized, placebo-controlled study","volume":"69","author":"Dougados","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1136\/annrheumdis-2017-212008","article-title":"Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritis","volume":"77","author":"Dougados","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/art.41667","article-title":"Tumor necrosis factor inhibitors reduce spinal radiographic progression in patients with radiographic axial spondyloarthritis: a longitudinal analysis from the Alberta prospective cohort","volume":"73","author":"Sepriano","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/rheumatology\/key364","article-title":"Risk of tuberculosis in patients with immune-mediated diseases on biological therapies: a population-based study in a tuberculosis endemic region","volume":"58","author":"Wang","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/rheumatology\/kex474","article-title":"Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study","volume":"57","author":"Balsa","year":"2018","journal-title":"Rheumatology (Oxford)"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000001986","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T19:09:55Z","timestamp":1748977795000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000001986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,9]]},"references-count":17,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000001986","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"type":"print","value":"0366-6999"},{"type":"electronic","value":"2542-5641"}],"subject":[],"published":{"date-parts":[[2022,3,9]]}}}